Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
274.46
+4.09 (+1.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
February 06, 2024
Via
Benzinga
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
December 29, 2023
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
December 08, 2023
Via
Benzinga
Expert Ratings for Alnylam Pharmaceuticals
November 15, 2023
Via
Benzinga
Earnings Outlook For Alnylam Pharmaceuticals
November 01, 2023
Via
Benzinga
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am
Via
Benzinga
Exposures
Product Safety
Why Newly Listed Korro Bio Shares Are Gaining Today
December 04, 2023
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
Via
Benzinga
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Expert Ratings for Alnylam Pharmaceuticals
October 16, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 11, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
September 29, 2023
Via
Benzinga
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
September 12, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
October 11, 2023
Via
Benzinga
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday
October 11, 2023
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in...
Via
Benzinga
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today?
October 09, 2023
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin-
Via
Benzinga
Exposures
Product Safety
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug
October 09, 2023
Shares skidded to their lowest point since September on the FDA's rejection.
Via
Investor's Business Daily
Exposures
Product Safety
2 Growth Stocks That Could Rocket Higher Before the End of 2023
October 08, 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 05, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
September 14, 2023
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug.
Via
Investor's Business Daily
Exposures
Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
September 14, 2023
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.
Via
InvestorPlace
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
September 11, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright